Wedbush Downgrades Aclaris Therapeutics to Neutral, Lowers Price Target to $3

Benzinga · 4d ago
Wedbush analyst Martin Fan downgrades Aclaris Therapeutics (NASDAQ:ACRS) from Outperform to Neutral and lowers the price target from $8 to $3.